Europe Epigenetics Diagnostic Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2021 –2028 |
 시장 규모(기준 연도) |
USD 1,292.28 Million |
 시장 규모(예측 연도) |
USD 3,268.01 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>유럽 후성유전학 진단 시장, 제품별(시약, 키트, 기구 및 소모품, 생물정보학 도구 및 효소), 기술(DNA 메틸화, 히스톤 메틸화, 크로마틴 구조, 히스톤 아세틸화, 대형 비코딩 RNA 및 마이크로RNA 변형), 치료 유형(히스톤 탈아세틸화효소(HDAC) 억제제, DNA 메틸트랜스퍼라제(DNMT) 억제제 및 기타), 응용 분야(종양학, 심혈관 질환, 대사 질환, 면역학, 염증성 질환, 감염성 질환 및 기타), 최종 사용자(학술 및 연구 기관, 제약 및 생명공학 회사, 계약 연구 기관(CRO) 및 기타), 유통 채널(직접 입찰 및 소매 판매), 국가(독일, 프랑스, 영국, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드, 이탈리아, 스페인, 러시아, 터키, 네덜란드, 스위스, 유럽의 나머지 지역) 산업 동향 및 예측 2028년.
시장 분석 및 통찰력: 유럽 에피제네틱스 진단 시장
유럽의 에피제네틱스 진단 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 12.7%의 CAGR로 성장하고 있으며 2020년의 1,292.28백만 달러에서 2028년까지 3,268.01백만 달러에 도달할 것으로 예상한다고 분석했습니다. 만성 질환의 높은 유병률과 효과적인 적용을 위한 에피제네틱스 진단에 대한 높은 수요는 예측 기간 동안 시장 수요를 촉진하는 주요 동인이 될 가능성이 높습니다.
후생유전학 진단은 외부 환경에 의해 발생하는 유전학, 세포 및 물리적 특성 변화, 발달 생물학을 연구하는 것입니다. 이는 유전자와 유전자형의 변화에 영향을 받지 않고 유전자를 읽는 세포의 능력에 영향을 미칩니다. 후생유전학 변화는 유전자형이 아닌 유기체의 표현형의 변화로 이어지고, 기본 DNA 및 RNA 시퀀스는 변하지 않습니다. 후생유전학 변화는 역동적이고 환경에 따라 변화하기 때문에 발달에 필수적입니다.
생물체의 유전적 발현은 후성유전학의 영향을 받으며, 이로 인해 후성유전학은 분자생물학 및 발생유전학에서 가장 중요한 분야가 되었습니다. National Center Institute, National Institute of Health, International Human Epigenome Consortium과 같은 기관은 후성유전학 분야와 관련된 연구 및 개발 활동을 자금 지원하고 있습니다. 후성유전학은 또한 암, 대사 질환 등과 같은 다양한 만성 질환을 치료하는 데 사용됩니다.
유럽 에피제네틱스 진단 시장 보고서는 시장 점유율, 새로운 개발, 국내 및 지역 시장 참여자의 영향에 대한 세부 정보를 제공하고, 새로운 수익 창출, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서 기회를 분석합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
유럽 에피제네틱스 진단 시장 범위 및 시장 규모
유럽의 에피제네틱스 진단 시장은 제품, 기술, 치료 유형, 응용 프로그램, 최종 사용자 및 유통 채널을 기반으로 하는 6개의 주요 세그먼트로 분류됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 제품 기준으로 유럽 에피제네틱스 진단 시장은 시약, 키트, 기기 및 소모품, 생물정보학 도구, 효소로 세분화됩니다. 2021년에는 시약 부문이 시장을 지배할 것으로 예상되는데, 시약은 주로 진단 분야에서 사용되고 있기 때문입니다.
- 기술에 따라 유럽의 에피제네틱스 진단 시장은 DNA 메틸화, 히스톤 메틸화, 크로마틴 구조, 히스톤 아세틸화, 대형 비코딩 RNA, 마이크로RNA 변형으로 세분화됩니다. 2021년에는 DNA 메틸화 기술이 다양한 에피제네틱스 진단에 사용되고 있기 때문에 DNA 메틸화 세그먼트가 시장을 지배할 것으로 예상됩니다.
- 치료 유형에 따라 유럽 에피제네틱 진단 시장은 히스톤 데아세틸라제(HDAC) 억제제, DNA 메틸트랜스퍼라제(DNMT) 억제제 등으로 세분화됩니다. 2021년에는 히스톤 데아세틸라제(HDAC) 억제제 세그먼트가 증식, 세포 주기 진행 및 분화와 같은 여러 생물학적 과정에서 중요한 역할을 하기 때문에 시장을 지배할 것으로 예상됩니다. 히스톤 데아세틸라제(HDAC) 및 그 억제제는 히스톤을 번역 후 수정하는 데 사용할 수 있습니다. 히스톤 코드는 다른 단백질이 읽고 인식하여 유전자 발현을 조절합니다.
- 유럽의 에피제네틱스 진단 시장은 응용 프로그램을 기준으로 종양학, 심혈관 질환, 대사 질환, 면역학, 염증성 질환 등으로 세분화됩니다. 2021년에는 에피제네틱스 진단이 다양한 암을 진단하는 데 사용되기 때문에 종양학 부문이 시장을 지배할 것으로 예상됩니다.
- 최종 사용자를 기준으로 유럽 에피제네틱스 진단 시장은 학술 및 연구 기관, 제약 및 생명공학 회사, 계약 연구 기관(CRO) 등으로 세분화됩니다. 2021년에는 학술 및 연구 기관 부문이 시장을 지배할 것으로 예상되는데, 연구 기관이 에피제네틱스 진단과 관련된 다양한 치료 분야에서 연구 개발을 가속화하는 데 필수적인 역할을 하기 때문입니다.
- 유통 채널을 기준으로 유럽 에피제네틱스 진단 시장은 직접 입찰과 소매 판매로 세분화됩니다. 2021년에는 마케팅 활동의 확대와 고객 서비스 개선으로 인해 직접 입찰 부문이 시장을 지배할 것으로 예상됩니다.
유럽 에피제네틱스 진단 시장 국가 수준 분석
유럽의 유전학 진단 시장을 분석하고, 제품, 기술, 치료 유형, 응용 분야, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.
유럽 유전학 진단 시장 보고서에서 다루는 국가는 독일, 프랑스, 이탈리아, 영국, 스페인, 네덜란드, 러시아, 스위스, 터키, 벨기에, 기타 유럽 국가입니다.
독일은 암 유병률의 증가, 조기 진단에 대한 사람들의 인식 증가, 의료 인프라의 확대로 인해 유럽의 유전학 진단 시장이 성장할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
유럽 에피제네틱스 진단 시장 에서 첨단 기술과 플레이어의 전략적 이니셔티브의 존재가 새로운 기회를 창출하고 있습니다.
유럽 에피제네틱스 진단 시장은 또한 제품 판매, 시장 발전의 영향, 에피제네틱스 진단 시장에 대한 지원과 함께 규제 시나리오의 변화와 함께 특정 산업에서 모든 국가의 성장에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2010년부터 2019년까지의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 유럽 에피제네틱스 진단 시장 점유율 분석
유럽 에피제네틱스 진단 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 범위, 응용 분야 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 치과 기구 시장과 관련된 회사의 초점에만 관련이 있습니다.
후생유전학 진단을 제공하는 주요 기업으로는 PerkinElmer Inc., Diagenode, F. Hoffman-La Roche Ltd, EPICYPHER, Cambridge Epigenetix (CEGX), Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Mnemo, Reaction Biology, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., Epizyme, Inc., GlaxoSmithKline plc., Eclipse BioInnovations, MDxHealth, Abcam plc, Salarius Pharmaceuticals, Inc., Datar Cancer Genetics 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
시장 참여자들의 전략적 이니셔티브와 유전학 진단을 위한 새로운 기술 발전은 다양한 치료법의 격차를 메우고 있습니다.
예를 들어,
- 2021년 5월, QIAGEN은 Mirati Therapeutics Inc.와 파트너십을 맺고 비소세포폐암(NSCLC)에 대한 KRAS-G12C 동반 진단법을 개발했습니다. NSCLC의 KRAS 돌연변이는 혁신적인 치료 옵션에 대한 충족되지 않은 요구가 있는 많은 소외된 환자 집단을 반영합니다. 이를 통해 QIAGEN은 NSCLC에서 KRAS 동반 진단 검사에서 입지를 강화할 수 있었습니다.
시장 참여자의 협력, 합작투자 및 기타 전략은 유전학 진단 시장에서 회사의 시장을 강화하고 있으며, 이를 통해 조직이 유전학 진단 시장에 대한 제공 사항을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE EPIGENETICS DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 REGULATIONS: EUROPE EPIGENETICS DIAGNOSITC MARKET
5.1 UNITED STATES
5.1.1 ROLE OF FDA
5.1.2 ROLE OF CDC AND HCFA
5.2 EUROPEAN UNION
5.3 FRANCE
5.4 AUSTRALIA
5.5 SOUTH KOREA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CANCER
6.1.2 INCREASE IN EUROPE GERIATRIC POPULATION
6.1.3 RISE IN RESEARCH & DEVELOPMENT (R&D) ACTIVITIES IN THE FIELD OF EPIGENETICS
6.1.4 PRESENCE OF ADVANCED TECHNOLOGIES TO IMPROVE DIAGNOSTIC EFFICIENCY
6.1.5 IMPROVING HEALTHCARE FACILITIES
6.2 RESTRAINTS
6.2.1 INADEQUACY IN IDENTIFICATION AND VALIDATION OF BIOMARKERS
6.2.2 HIGH COST OF EPIGENETICS DIAGNOSTIC EQUIPMENT
6.3 OPPORTUNITIES
6.3.1 WIDE RANGE OF APPLICATION
6.3.2 PROMOTER METHYLATION IN DIFFERENT TYPES OF CANCER
6.3.3 EMERGING MARKETS
6.3.4 INCREASING HEALTHCARE EXPENDITURE
6.3.5 RISING PER CAPITA INCOME
6.4 CHALLENGES
6.4.1 ESCALATING PRODUCT RECALL
6.4.2 SHORTAGE OF SKILLED PERSONNEL
6.4.3 EMERGENCE OF COVID-19
6.4.4 LACK OF ACCESSIBILITY
7 COVID-19 IMPACT ON EUROPE EPIGENETICS DIAGNOSTIC MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID 19
7.5 CONCLUSION:
8 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 REAGENTS
8.2.1 ANTIBODIES
8.2.2 BUFFERS
8.2.3 HISTONES
8.2.4 MAGNETIC BEADS
8.2.5 PRIMERS
8.2.6 OTHERS
8.3 KITS
8.3.1 CHIP SEQUENCING KIT
8.3.2 WHOLE GENOMIC AMPLIFICATION KIT
8.3.3 BISULFITE CONVERSION KIT
8.3.4 5-HMC & 5-MC ANALYSIS KITS
8.3.5 RNA SEQUENCING KIT
8.3.6 OTHERS
8.4 INSTRUMENTS & CONSUMABLES
8.4.1 NEXT-GENERATION SEQUENCERS
8.4.2 QPCR
8.4.3 MASS SPECTROMETERS
8.4.4 SONICATORS
8.4.5 OTHERS
8.5 BIOINFORMATICS TOOLS
8.6 ENZYMES
8.6.1 DNA-MODIFYING ENZYMES
8.6.2 PROTEIN-MODIFYING ENZYMES
8.6.3 RNA-MODIFYING ENZYMES
8.6.4 OTHERS
9 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 DNA METHYLATION
9.2.1 REAGENTS
9.2.2 KITS
9.2.3 INSTRUMENTS & CONSUMABLES
9.2.4 ENZYMES
9.3 HISTONE METHYLATION
9.3.1 REAGENTS
9.3.2 KITS
9.3.3 INSTRUMENTS & CONSUMABLES
9.3.4 ENZYMES
9.4 HISTONE ACETYLATION
9.4.1 REAGENTS
9.4.2 KITS
9.4.3 INSTRUMENTS & CONSUMABLES
9.4.4 ENZYMES
9.5 LARGE NON-CODING RNA
9.5.1 REAGENTS
9.5.2 KITS
9.5.3 INSTRUMENTS & CONSUMABLES
9.5.4 ENZYMES
9.6 MICRORNA MODIFICATION
9.6.1 REAGENTS
9.6.2 KITS
9.6.3 INSTRUMENTS & CONSUMABLES
9.6.4 ENZYMES
9.7 CHROMATIN STRUCTURES
9.7.1 REAGENTS
9.7.2 KITS
9.7.3 INSTRUMENTS & CONSUMABLES
9.7.4 ENZYMES
10 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY
10.1 OVERVIEW
10.2 HISTONE DEACETYLASE (HDAC) INHIBITORS
10.3 DNA METHYLTRANSFERASE (DNMT) INHIBITORS
10.4 OTHERS
11 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.2.1 SOLID TUMORS
11.2.2 LIQUID TUMORS
11.3 CARDIOVASCULAR DISEASES
11.4 METABOLIC DISEASES
11.4.1 METABOLIC SYNDROME
11.4.2 TYPE 2 DIABETES (T2D)
11.4.3 OTHERS
11.5 IMMUNOLOGY
11.6 INFLAMMATORY DISEASES
11.7 INFECTIOUS DISEASES
11.8 OTHERS
12 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 ACADEMIC AND RESEARCH INSTITUTES
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
12.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
12.5 OTHERS
13 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 U.K.
14.1.3 FRANCE
14.1.4 SPAIN
14.1.5 ITALY
14.1.6 BELGIUM
14.1.7 NETHERLANDS
14.1.8 RUSSIA
14.1.9 SWITZERLAND
14.1.10 TURKEY
14.1.11 REST OF EUROPE
15 EUROPE EPIGENETICS DIAGNOSTIC MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ILLUMINA, INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 MERCK KGAA
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 BIO-RAD LABORATORIES, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F. HOFFMANN-LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 RECENT FINANCIALS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 AGILENT TECHNOLOGIES, INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PERKINELMER INC
17.7.1 COMPANY SNAPSHOT
17.7.2 RECENT FINANCIALS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 QIAGEN
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 ABCAM PLC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 ACTIVEMOTIF
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 BLUESTAR GENOMICS INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 CAMBRIDGE EPIGENETIX (CEGX)
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 DATAR CANCER GENETICS
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 DIAGENODE
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 ECLIPSE BIOINNOVATIONS
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ENZO LIFE SCIENCES, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 EPICYPHER
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENTS
17.18 EPIGENOMICS AG
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 EPIGENTEK GROUP INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 EPIZYME, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 GLAXOSMITHKLINE PLC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 MDXHEALTH
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 MNEMO
17.23.1 COMPANY SNAPSHOT
17.23.2 PRODUCT PORTFOLIO
17.23.3 RECENT DEVELOPMENT
17.24 NEW ENGLAND BIOLABS
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
17.25.1 COMPANY SNAPSHOT
17.25.2 RECENT FINANCIALS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENTS
17.26 PROMEGA CORPORATION
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 REACTION BIOLOGY
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 SALARIUS PHARMACEUTICALS, INC.
17.28.1 COMPANY SNAPSHOT
17.28.2 RECENT FINANCIALS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENTS
17.29 ZYMO RESEARCH CORPORATION
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 HEALTH CARE FACILITIES
TABLE 2 PER CAPITA AMOUNTS: UNITED STATES (1960–2017 YEARS)
TABLE 3 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 EUROPE REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 6 EUROPE KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 8 EUROPE INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 EUROPE INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 10 EUROPE BIOINFORMATICS TOOLS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 13 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 14 EUROPE DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 EUROPE DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 16 EUROPE HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 EUROPE HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 18 EUROPE HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 20 EUROPE LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 22 EUROPE MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 24 EUROPE CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 26 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 27 EUROPE HISTONE DEACETYLASE (HDAC) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 EUROPE DNA METHYLTRANSFERASE (DNMT) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE CARDIOVASCULAR DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE IMMUNOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE INFLAMMATORY DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 EUROPE INFECTIOUS DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 EUROPE CONTRACT RESEARCH ORGANIZATIONS (CROS) IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 EUROPE OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 EUROPE DIRECT TENDER IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 EUROPE RETAIL SALES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 49 EUROPE EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 50 EUROPE REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 51 EUROPE KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 EUROPE INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 EUROPE ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 54 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 55 EUROPE DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 EUROPE HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 EUROPE HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 EUROPE LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 EUROPE MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 EUROPE CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 62 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 EUROPE ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 64 EUROPE METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 65 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 EUROPE EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 GERMANY EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 68 GERMANY REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 69 GERMANY KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 70 GERMANY INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 71 GERMANY ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 72 GERMANY EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 GERMANY DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 GERMANY HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 GERMANY HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 76 GERMANY LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 77 GERMANY MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 78 GERMANY CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 79 GERMANY EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 80 GERMANY EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 81 GERMANY ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 GERMANY METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 GERMANY EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 GERMANY EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 U.K. EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 86 U.K. REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 U.K. KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 U.K. INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 89 U.K. ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 90 U.K. EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 91 U.K. DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 92 U.K. HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 93 U.K. HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 94 U.K. LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 95 U.K. MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 96 U.K. CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 97 U.K. EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 98 U.K. EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 99 U.K. ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 100 U.K. METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 101 U.K. EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 U.K. EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 103 FRANCE EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 104 FRANCE REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 105 FRANCE KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 106 FRANCE INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 107 FRANCE ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 108 FRANCE EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 109 FRANCE DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 110 FRANCE HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 111 FRANCE HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 112 FRANCE LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 113 FRANCE MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 114 FRANCE CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 115 FRANCE EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 116 FRANCE EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 FRANCE ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 118 FRANCE METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 119 FRANCE EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 120 FRANCE EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 121 SPAIN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 122 SPAIN REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 123 SPAIN KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 124 SPAIN INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 125 SPAIN ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 SPAIN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 127 SPAIN DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 128 SPAIN HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 129 SPAIN HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 130 SPAIN LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 131 SPAIN MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 132 SPAIN CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 133 SPAIN EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 134 SPAIN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 SPAIN ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 136 SPAIN METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 137 SPAIN EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 138 SPAIN EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 139 ITALY EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 140 ITALY REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 141 ITALY KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 142 ITALY INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 143 ITALY ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 144 ITALY EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 145 ITALY DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 146 ITALY HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 147 ITALY HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 148 ITALY LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 149 ITALY MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 150 ITALY CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 151 ITALY EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 152 ITALY EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 153 ITALY ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 154 ITALY METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 155 ITALY EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 156 ITALY EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 157 BELGIUM EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 158 BELGIUM REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 159 BELGIUM KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 160 BELGIUM INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 161 BELGIUM ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 162 BELGIUM EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 163 BELGIUM DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 164 BELGIUM HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 165 BELGIUM HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 166 BELGIUM LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 167 BELGIUM MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 168 BELGIUM CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 169 BELGIUM EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 170 BELGIUM EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 171 BELGIUM ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 172 BELGIUM METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 173 BELGIUM EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 174 BELGIUM EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 175 NETHERLANDS EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 176 NETHERLANDS REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 177 NETHERLANDS KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 178 NETHERLANDS INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 179 NETHERLANDS ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 180 NETHERLANDS EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 181 NETHERLANDS DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 182 NETHERLANDS HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 183 NETHERLANDS HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 184 NETHERLANDS LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 185 NETHERLANDS MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 186 NETHERLANDS CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 187 NETHERLANDS EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 188 NETHERLANDS EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 189 NETHERLANDS ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 190 NETHERLANDS METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 191 NETHERLANDS EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 192 NETHERLANDS EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 193 RUSSIA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 194 RUSSIA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 195 RUSSIA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 196 RUSSIA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 197 RUSSIA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 198 RUSSIA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 199 RUSSIA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 200 RUSSIA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 201 RUSSIA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 202 RUSSIA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 203 RUSSIA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 204 RUSSIA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 205 RUSSIA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 206 RUSSIA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 207 RUSSIA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 208 RUSSIA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 209 RUSSIA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 210 RUSSIA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 211 SWITZERLAND EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 212 SWITZERLAND REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 213 SWITZERLAND KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 214 SWITZERLAND INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 215 SWITZERLAND ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 216 SWITZERLAND EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 217 SWITZERLAND DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 218 SWITZERLAND HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 219 SWITZERLAND HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 220 SWITZERLAND LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 221 SWITZERLAND MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 222 SWITZERLAND CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 223 SWITZERLAND EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 224 SWITZERLAND EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 225 SWITZERLAND ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 226 SWITZERLAND METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 227 SWITZERLAND EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 228 SWITZERLAND EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 229 TURKEY EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 230 TURKEY REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 231 TURKEY KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 232 TURKEY INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 233 TURKEY ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 234 TURKEY EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 235 TURKEY DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 236 TURKEY HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 237 TURKEY HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 238 TURKEY LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 239 TURKEY MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 240 TURKEY CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 241 TURKEY EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 242 TURKEY EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 243 TURKEY ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 244 TURKEY METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 245 TURKEY EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 246 TURKEY EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 247 REST OF EUROPE EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 EUROPE EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 EUROPE EPIGENETICS DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE EPIGENETICS DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 EUROPE EPIGENETICS DIAGNOSTIC MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE EPIGENETICS DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE EPIGENETICS DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE EPIGENETICS DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE EPIGENETICS DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE EPIGENETICS DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE EUROPE EPIGENETICS DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE EPIGENETICS DIAGNOSTIC MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE EPIGENETICS DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE EPIGENETICS DIAGNOSTIC MARKET
FIGURE 15 EPIGENETIC REGULATION IN CANCER
FIGURE 16 PREVALENCE OF CANCER WORLDWIDE
FIGURE 17 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES WORLDWIDE
FIGURE 18 NORTH AMERICA AGING POPULATION (IN MILLIONS)
FIGURE 19 GERIATRIC POPULATION WORLWIDE
FIGURE 20 NCI FUNDING FOR CANCER RESEARCH
FIGURE 21 EPIGENETIC IVD TESTS
FIGURE 22 THREE NEXT GENERATION SEQUENCING PLATFORMS
FIGURE 23 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2020
FIGURE 24 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 25 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 26 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 27 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2020
FIGURE 28 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 29 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 30 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2020
FIGURE 32 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2021-2028 (USD MILLION)
FIGURE 33 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, CAGR (2021-2028)
FIGURE 34 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, LIFELINE CURVE
FIGURE 35 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2020
FIGURE 36 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 37 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 38 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 39 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2020
FIGURE 40 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 41 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY END USER, CAGR (2021-2028)
FIGURE 42 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 45 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 46 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 EUROPE EPIGENETICS DIAGNOSTIC MARKET: SNAPSHOT (2020)
FIGURE 48 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020)
FIGURE 49 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 EUROPE EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT (2021-2028)
FIGURE 52 EUROPE EPIGENETICS DIAGNOSTIC MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
